<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of the pulmonary complications of sickle cell disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of the pulmonary complications of sickle cell disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of the pulmonary complications of sickle cell disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth S Klings, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shaina Willen, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jess Mandel, MD, MACP, ATSF, FRCP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elliott P Vichinsky, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 23, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Sickle cell disease (SCD) encompasses a group of hemoglobinopathies characterized by amino acid substitutions in the beta globin chain. Sickle cell anemia is caused by homozygous sickle mutation (Hb SS). The sickle mutation causes substitution of a valine for glutamic acid as the seventh amino acid of the beta globin chain. The resulting hemoglobin tetramer (alpha2/betaS2) is poorly soluble when deoxygenated. Other forms of SCD include Hb SC disease, in which an individual is a compound heterozygote for the sickle mutation and hemoglobin C (created by substitution of lysine for glutamic acid as the seventh amino acid), and sickle-beta<sup>+</sup>-thalassemia or sickle beta<sup>0</sup>- thalassemia, in which one beta globin allele has the Hb S mutation and the other has a beta thalassemia variant with reduced or absent production of beta globin.</p><p>The chronic pulmonary manifestations of SCD will be reviewed here [<a href="#rid1">1,2</a>]. Other aspects of SCD care, including the diagnosis and management and acute pulmonary presentations, are discussed separately. (See  <a class="medical medical_review" href="/d/html/7119.html" rel="external">"Overview of the clinical manifestations of sickle cell disease"</a> and  <a class="medical medical_review" href="/d/html/7113.html" rel="external">"Diagnosis of sickle cell disorders"</a> and  <a class="medical medical_review" href="/d/html/14519.html" rel="external">"Sickle cell disease in infancy and childhood: Routine health care maintenance and anticipatory guidance"</a> and  <a class="medical medical_review" href="/d/html/16353.html" rel="external">"Acute chest syndrome (ACS) in sickle cell disease (adults and children)"</a> and  <a class="medical medical_review" href="/d/html/7114.html" rel="external">"Overview of the management and prognosis of sickle cell disease"</a>.)</p><p class="headingAnchor" id="H1155883924"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>Deoxygenated sickle hemoglobin  (<a class="graphic graphic_picture graphicRef64449" href="/d/graphic/64449.html" rel="external">picture 1</a>) is the primary pathophysiologic event responsible for vaso-occlusive complications of SCD [<a href="#rid3">3</a>]. Vaso-occlusive phenomena and hemolysis are the clinical hallmarks of SCD and result in recurrent painful episodes referred to as vaso-occlusive events (VOEs; previously called sickle cell crisis) (see  <a class="medical medical_review" href="/d/html/7144.html" rel="external">"Acute vaso-occlusive pain management in sickle cell disease", section on 'Terms and language we avoid'</a>). Details of the pathophysiology of SCD are provided separately. (See  <a class="medical medical_review" href="/d/html/7135.html" rel="external">"Pathophysiology of sickle cell disease"</a>.)</p><p class="headingAnchor" id="H879459914"><span class="h1">ACUTE CHEST SYNDROME</span><span class="headingEndMark"> — </span>Acute chest syndrome (ACS) is the most common form of acute pulmonary disease in patients with SCD, occurring in almost one-half of patients. ACS is defined as a new segmental opacity on chest radiograph accompanied by fever and/or respiratory symptoms in a patient with SCD. Etiologies include pulmonary vaso-occlusion and ischemia, pneumonia, fat embolization, and thrombosis (either intravascular or thromboembolic). Infection remains a significant cause of ACS, especially in children, and infectious etiologies are essential to investigate and treat [<a href="#rid4">4</a>]. Discussions of the ACS in children, adolescents, and adults are presented separately. (See  <a class="medical medical_review" href="/d/html/16353.html" rel="external">"Acute chest syndrome (ACS) in sickle cell disease (adults and children)"</a>.)</p><p class="headingAnchor" id="H28220829"><span class="h1">CHRONIC DYSPNEA</span><span class="headingEndMark"> — </span>Dyspnea is a common yet underreported symptom in SCD, particularly in adults. Many SCD patients begin to experience subtle declines in their exercise capacity in early to late adolescence, and a careful history will often reveal self-limitations on previously performed sports and exertional activities. This subtle dyspnea becomes more overt as these patients reach adulthood. Screening questionnaires of 147 adults with Hb SS and Hb SC have helped to characterize this symptom more objectively. Approximately 50 percent of adults with Hb SS and 40 percent of those with Hb SC experience dyspnea with mild to moderate exertion [<a href="#rid5">5</a>].</p><p>The etiology of chronic dyspnea in SCD is likely multifactorial. While anemia is an important contributor, other explanations for dyspnea often coexist. A careful history (including specific questions about exercise limitations and level of conditioning), physical examination, comparison of hemoglobin level with baseline values, pulmonary function tests, and ambulatory oximetry are recommended to fully characterize dyspnea in this population  (<a class="graphic graphic_table graphicRef94508" href="/d/graphic/94508.html" rel="external">table 1</a>) [<a href="#rid6">6</a>].</p><p>Generally, this initial evaluation will provide clues as to the etiology of chronic dyspnea and direct further studies and management, as described in the following sections. Common causes of dyspnea in chronic SCD include anemia, deconditioning, asthma, pulmonary hypertension, venous thromboembolism, pulmonary fibrosis from recurrent acute chest events, and myocardial dysfunction. These conditions are discussed below and separately. (See  <a class="medical medical_review" href="/d/html/94999.html" rel="external">"Pulmonary hypertension associated with sickle cell disease"</a> and  <a class="medical medical_review" href="/d/html/7119.html" rel="external">"Overview of the clinical manifestations of sickle cell disease", section on 'Cardiac complications'</a> and  <a class="medical medical_review" href="/d/html/7119.html" rel="external">"Overview of the clinical manifestations of sickle cell disease", section on 'Anemia'</a>.)</p><p class="headingAnchor" id="H4159695996"><span class="h1">ASTHMA</span><span class="headingEndMark"> — </span>Asthma is common in patients with SCD, particularly among children and adolescents [<a href="#rid7">7,8</a>]. As an example, in a case control study, asthma was more common among 80 children with SCD than among ethnically matched controls (48 versus 22 percent) [<a href="#rid9">9</a>]. Similarly, small cohort studies suggest that children with SCD are at increased risk for developing airway hyperreactivity and airway obstruction [<a href="#rid10">10,11</a>].</p><p>The interrelationship of asthma and SCD is complex and not well understood. In three large cohort studies examining the interrelationship of asthma and SCD, children with a diagnosis of asthma have increased rates of both pain and acute chest syndrome (ACS) [<a href="#rid12">12</a>]. Additionally, children with a history of ACS are more likely to develop asthma [<a href="#rid9">9</a>]. It is thought that severe airway narrowing due to asthma can lead to local hypoxia and promote sickling and systemic inflammation [<a href="#rid13">13</a>]. In addition, recurrent ACS may contribute to lung inflammation and increased bronchial hyperreactivity [<a href="#rid14">14-16</a>]. While some patients clearly have an atopic phenotype [<a href="#rid9">9</a>], which has been associated with an increased risk for ACS in children [<a href="#rid17">17</a>] others do not, suggesting that nonallergic mediated inflammation also plays a role in the pathogenesis of asthma in patients with SCD [<a href="#rid14">14</a>]. The contribution of asthma to ACS is discussed separately. (See  <a class="medical medical_review" href="/d/html/16353.html" rel="external">"Acute chest syndrome (ACS) in sickle cell disease (adults and children)", section on 'Overview of pathogenesis'</a>.)</p><p>The diagnosis of asthma in people with SCD can be challenging because the symptoms and signs of asthma (eg, shortness of breath, cough, wheeze) overlap with other pulmonary complications of SCD. The presence of intermittent or chronic symptoms and wheezing on examination should lead to an evaluation for asthma. As in other settings, the diagnosis of asthma is based upon the demonstration of variable airflow limitation, preferably by spirometry before and after bronchodilator, and exclusion of alternate diagnoses. In addition to asthma, the differential diagnosis of wheezing in a patient with SCD includes processes such as decompensated heart failure, viral infection, gastroesophageal reflux, congenital abnormalities (eg, vascular ring, congenital lobar emphysema), bronchiectasis, tuberculosis, and vocal cord dysfunction. (See <a class="local">'Pulmonary function test abnormalities'</a> below and  <a class="medical medical_review" href="/d/html/5742.html" rel="external">"Asthma in children younger than 12 years: Initial evaluation and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/543.html" rel="external">"Asthma in adolescents and adults: Evaluation and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/563.html" rel="external">"Evaluation of wheezing illnesses other than asthma in adults"</a>.)</p><p>Management of asthma in SCD should follow guidelines established for non-SCD patients with asthma. (See  <a class="medical medical_review" href="/d/html/547.html" rel="external">"An overview of asthma management"</a> and  <a class="medical medical_review" href="/d/html/90904.html" rel="external">"Asthma in children younger than 12 years: Overview of initiating therapy and monitoring control"</a>.)</p><p class="headingAnchor" id="H55813951"><span class="h1">PULMONARY FUNCTION TEST ABNORMALITIES</span><span class="headingEndMark"> — </span>Pulmonary function tests (PFTs) are often abnormal in adult and pediatric patients with SCD. In these discussions, pediatric patients are defined by an age &lt;18 years [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/d/html/6969.html" rel="external">"Overview of pulmonary function testing in adults"</a> and  <a class="medical medical_review" href="/d/html/5735.html" rel="external">"Overview of pulmonary function testing in children"</a>.)</p><p class="headingAnchor" id="H700904466"><span class="h2">Adults</span><span class="headingEndMark"> — </span>PFTs are generally obtained in adults with SCD, but practice varies. While some experts obtain PFTs in response to a report of dyspnea or to monitor known asthma, others obtain them on a routine basis. In a cross-sectional evaluation from the multicenter Cooperative Study of Sickle Cell Disease, pulmonary function was assessed in 310 Black adults with Hb SS disease irrespective of symptoms [<a href="#rid19">19</a>]. Only 10 percent of these patients had completely normal PFTs. The following abnormal PFT patterns were found [<a href="#rid19">19-21</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Restrictive pattern – 74 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Isolated low diffusing capacity for carbon monoxide (DLCO) – 13 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Mixed obstructive/restrictive pattern – 2 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Obstructive pattern – 1 percent</p><p></p><p>These patterns were not significantly different between individuals with or without a prior history of acute chest syndrome (ACS). Similar findings were reported in another cohort of adult patients [<a href="#rid22">22</a>]. Even when corrected for anemia, the DLCO is often low, particularly in patients with a history of ACS (<a class="calc calc_patient" href="/d/html/83750.html" rel="external">calculator 1</a> and <a class="calc calc_patient" href="/d/html/89706.html" rel="external">calculator 2</a>) [<a href="#rid19">19</a>].</p><p>One longitudinal study of pulmonary function in adults with SCD demonstrated an average decline in forced expiratory volume in one second (FEV<sub>1</sub>) of 49 mL/year compared with 20 to 26 mL/year in the general population [<a href="#rid23">23</a>]. The decline was unrelated to smoking status. In a subsequent cohort of 193 adults with SCD who had at least two spirometry tests over up to 10 years of monitoring, FEV<sub>1</sub> declined by 23 mL/year (95% CI -28 to -18) [<a href="#rid24">24</a>]. In this cohort, the rate of decline was similar to that observed in adult patients with cystic fibrosis.</p><p>Reduced FEV<sub>1</sub> percent predicted is associated with an increased risk of death in patients with SCD, as evidenced by a cohort of 430 adults with SCD, mean age 32.6±9.5 (range 21.0-67.8) years, who were monitored for a median of 5.5 years, during which 63 deaths occurred [<a href="#rid25">25</a>]. In the final multivariable model, a lower FEV<sub>1</sub> percent predicted was associated with increased hazard ratio (HR) of death (HR 1.02, 95% CI 1.00-1.04; p = 0.037).</p><p>Pulse oxygen saturation (SpO<sub>2</sub>) is reduced in adults with SCD, with steady-state baseline values below 96 percent in an appreciable portion of patients. Significant desaturations occur with exertion and with sleep. A widened alveolar-arterial oxygen gradient is observed both at rest and with exercise [<a href="#rid26">26</a>]. (See <a class="local">'Sleep-disordered breathing'</a> below.)</p><p class="headingAnchor" id="H700904472"><span class="h2">Children</span><span class="headingEndMark"> — </span>Children and adolescents with SCD may have abnormal PFTs, and asthma is common among children with SCD. Thus, we suggest performing spirometry in children with SCD every one to three years, using the more frequent intervals for those with dyspnea, a history of asthma or recurrent wheezing, or accentuated elevations in hemolytic markers [<a href="#rid27">27</a>].</p><p>While restrictive physiology, as observed in adults, can occur in the pediatric age group, a number of studies of nonreferred cohorts report a predominance of obstructive disease in those with abnormal lung function [<a href="#rid28">28,29</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective study of 127 children and adolescents with SCD found that obstructive airways disease was present in 35 percent, while restrictive physiology occurred in 26 percent [<a href="#rid29">29</a>]. The remaining 39 percent had normal pulmonary function.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a subsequent prospective study, 146 patients aged 7 to 20 years with Hb SS or Hb S-beta<sup>0</sup> thalassemia were evaluated with PFTs [<a href="#rid27">27</a>]. In this study, 39 percent had abnormal PFTs, with an obstructive pattern present in 19 percent, restrictive in 9 percent, and abnormal but not characterized in 11 percent. Increasing age, a family or patient history of asthma or wheezing, and an elevated lactate dehydrogenase (LDH) level reflective of hemolysis were all predictive of obstructive physiology.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study of 149 nonreferred Hb SS or Hb S-beta<sup>0</sup> thalassemia children and adolescents participating in the National Institutes of Health (NIH)-funded Sleep and Asthma Cohort Study found that percentages of normal, obstructive, restrictive, nonspecific, and mixed lung function patterns were 70, 16, 7, 6, and 1, respectively [<a href="#rid30">30</a>]. Lung function pattern was not predictive of future vaso-occlusive events or ACS nor reflective of prior history of ACS, thus calling into question the predictive role of PFTs in this population.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective study involving 19 children and young adults (ages 2 to 21 years) who underwent haploidentical stem cell transplantation, pulmonary functions including FEV<sub>1</sub>/forced vital capacity (FVC), total lung capacity (TLC), and DLCO were stable to improved two years posttransplant compared with baseline values [<a href="#rid31">31</a>]. Specific airway conductance was significantly improved at two years (p&lt;0.004).</p><p></p><p>Longitudinal studies have shown variability in the magnitude of decline in FEV<sub>1</sub> percent predicted over time among children. In a single-institution prospective study of 92 children, a decline of 1.7 percent per year was noted in one cohort (47 children ages 3 to 13 years examined over two years) and 0.9 percent per year in a second (45 children ages 4 to 16 years examined over 10 years) [<a href="#rid32">32</a>]. Examination of 197 children ages 4 to 19 years from the Sleep and Asthma Cohort Study showed a small decline of 0.3 percent in FEV<sub>1</sub> percent predicted over time (approximately five years). Furthermore, none of the examined clinical covariates (sex, baseline laboratory values, rate of pain or ACS, asthma diagnosis, or treatment with <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a>) were associated with this decline [<a href="#rid33">33</a>]. Therefore, both the degree of decline in lung function from the pediatric population to adulthood and the factors impacting this decline are variable and unclear.</p><p>Measurements of SpO<sub>2</sub> are typically below normal in children with SCD. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective cohort study of 130 children from the Cooperative Study for Sickle Cell Disease (CSSCD), mean and median daytime SpO<sub>2</sub> were 94 and 95 percent, respectively [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar results (95 to 96 percent) were seen in three other studies of mean daytime SpO<sub>2</sub> [<a href="#rid35">35-37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study of 39 SCD patients (median age of 10.8 years) found that 45 percent had post-exercise hypoxemia defined as an SpO<sub>2</sub> decrease ≥3 percent after a six-minute walk test [<a href="#rid38">38</a>].</p><p></p><p>Daytime SpO<sub>2</sub> does not appear to independently predict subsequent vaso-occlusive or acute chest episodes [<a href="#rid34">34</a>]. In addition, there are no data correlating daytime SpO<sub>2</sub> with nighttime SpO<sub>2</sub>, which generally is lower than daytime values [<a href="#rid34">34</a>]. Nevertheless, SpO<sub>2</sub> values below baseline measurements for individual patients with SCD, either at rest or following exercise, are useful in detecting and monitoring for the presence of pulmonary complications.</p><p class="headingAnchor" id="H18"><span class="h1">PULMONARY HYPERTENSION</span><span class="headingEndMark"> — </span>Pulmonary hypertension (PH) is a relatively frequent (occurring in 6 to 11 percent of adults) and severe complication of SCD and an independent risk factor for mortality [<a href="#rid2">2</a>]. Exertional dyspnea is a clue to the presence of PH; initial evaluation typically includes Doppler echocardiography, measurement of N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, and a six-minute walk test. PH may be suspected on the basis of exertional dyspnea and noninvasive testing, but definitive diagnosis requires right heart catheterization (RHC) with demonstration of a resting mean pulmonary arterial pressure (mPAP) ≥25 mmHg  (<a class="graphic graphic_algorithm graphicRef94509" href="/d/graphic/94509.html" rel="external">algorithm 1</a>). Updated criteria for PH include an mPAP ≥20 mmHg, but this value has not been specifically studied in patients with SCD. The prevalence, pathogenesis, screening and risk stratification, diagnosis, and treatment of PH in SCD are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/94999.html" rel="external">"Pulmonary hypertension associated with sickle cell disease"</a>.)</p><p class="headingAnchor" id="H55814861"><span class="h1">VENOUS THROMBOEMBOLISM AND PULMONARY THROMBOSIS</span><span class="headingEndMark"> — </span>SCD is a hypercoagulable state with reported abnormalities in coagulation and platelet function [<a href="#rid39">39</a>]. Autopsy examinations of the lungs from patients with SCD reveal fibrin thrombi in larger arteries with or without infarction, and extensive thrombosis in smaller arteries (in situ thrombosis) [<a href="#rid40">40-43</a>]. As an example, in a series of 21 patients with SCD with sudden death, pulmonary thromboembolism and microvascular occlusive thrombi were noted in 38 and 28 percent, respectively [<a href="#rid43">43</a>]. A separate autopsy study of 30 patients from Brazil revealed recent thrombosis in 80 percent and old thrombosis in 43 percent [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H4038606595"><span class="h2">Frequency of venous and arterial thrombosis</span><span class="headingEndMark"> — </span>Several studies suggest that the frequencies of venous thromboembolism (VTE) and pulmonary arterial thrombosis are increased among patients with SCD [<a href="#rid45">45-48</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a cross-sectional study of 404 patients with SCD, a history of VTE was noted in 25 percent and noncatheter-related VTE in 19 percent [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Data from the National Hospital Discharge Survey revealed that a discharge diagnosis of pulmonary embolism (PE) was approximately three times higher among patients with SCD than without, although the risk of deep vein thrombosis (DVT) was not increased [<a href="#rid48">48</a>]. Compared with non-SCD patients with a PE, those with SCD and a PE were significantly older and had a longer length of stay, greater severity of illness, and higher mortality [<a href="#rid47">47</a>]. A separate study also reported higher rates of PE than DVT in patients with SCD [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Data from the California Patient Discharge Database (CPDD) revealed that in 6237 patients with SCD, 696 (11 percent) had an incident VTE by age 40. Among those with severe disease (defined as three or more hospitalizations in the prior year), 17 percent had sustained a VTE, and the five-year recurrence rate in these patients was 37 percent [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among 877 SCD patients in the CPDD with an incident VTE, the cumulative incidence of recurrence at one year was 13.2 percent (95% CI 11.0-15.5 percent) and at five years was 24.1 percent (95% CI 21.2-27.1 percent). Risk factors for VTE recurrence included more severe SCD (HR 2.41, 95% CI 1.67-3.47), lower extremity DVT as the incident event (HR 1.64, 95% CI 1.17-2.30), and pneumonia/acute chest syndrome (ACS) (HR 1.68, 95% CI 1.15-2.45). The cumulative incidence of bleeding was 4.9 percent (95% CI 3.5-6.4 percent) at six months and 7.9 percent (95% CI 6.2-9.8 percent) at one year [<a href="#rid51">51</a>].</p><p></p><p class="headingAnchor" id="H450526321"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>The evaluation of acute VTE is slightly different in patients with SCD than without. The D-dimer and the modified Geneva score, methods used to screen for VTE, have limited value in SCD [<a href="#rid45">45,52</a>]. D-dimer levels are increased in SCD relative to controls and fluctuate with vaso-occlusive events [<a href="#rid39">39</a>]. The poor predictive value of scoring systems is likely due to the overlap between the signs used in the scoring systems for VTE and the characteristic features of ACS. Thus, we typically perform a computed tomography pulmonary angiogram (CTPA) when VTE is suspected due to factors such as acute onset or worsening of dyspnea, presence of lower extremity edema, or lack of expected improvement in pulse oxygen saturation (SpO<sub>2</sub>) with treatment of ACS, or when the patient has other risk factors for VTE (eg, long-term central venous catheter, recent surgery [particularly hip replacement], pregnancy, prior surgical splenectomy, or immobility) [<a href="#rid26">26,39</a>]. (See  <a class="medical medical_review" href="/d/html/8261.html" rel="external">"Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"</a>.)</p><p class="headingAnchor" id="H2464452788"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>The optimal treatment of confirmed acute VTE and pulmonary thrombosis in SCD is not known, but the ongoing thrombotic risk and high rate of recurrence has led to the practice of lifelong anticoagulation after a first-time VTE in SCD patients without a contraindication [<a href="#rid53">53</a>]. However, due to the risks of anticoagulation in patients with worsening anemia due to SCD, we typically delay full anticoagulation pending the results of the CTPA unless the clinical suspicion is high. (See  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults"</a> and  <a class="medical medical_review" href="/d/html/95336.html" rel="external">"Venous thromboembolism: Initiation of anticoagulation"</a>.)</p><p>The management of chronic VTE in patients with pulmonary hypertension (PH) is described separately. (See  <a class="medical medical_review" href="/d/html/94999.html" rel="external">"Pulmonary hypertension associated with sickle cell disease", section on 'Long-term anticoagulation'</a>.)</p><p>All adults with SCD admitted to the hospital with an acute medical illness, including pneumonia and PH, should receive VTE prophylaxis. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/7114.html" rel="external">"Overview of the management and prognosis of sickle cell disease", section on 'Thromboembolism prophylaxis'</a>.)</p><p class="headingAnchor" id="H55815097"><span class="h1">PULMONARY FIBROSIS</span><span class="headingEndMark"> — </span>Pulmonary fibrosis (chronic scarring of the lung parenchyma) is occasionally seen in patients with recurrent episodes of acute chest syndrome (ACS) with pulmonary infarction. In the past, the term "sickle cell chronic lung disease" (SCCLD) was used to describe the association of pulmonary fibrosis and pulmonary hypertension in SCD, but now these processes are considered individually and the term "sickle cell chronic lung disease" is considered obsolete [<a href="#rid2">2,54,55</a>].</p><p>The clinical manifestations of pulmonary fibrosis in SCD include dyspnea and scattered areas of honeycombing on high-resolution computed tomography (HRCT) of the chest. A restrictive pattern on pulmonary function tests (PFTs) is common in adults with SCD and might be expected to be present in SCD-associated pulmonary fibrosis, possibly in association with a reduction in diffusing capacity for carbon monoxide (DLCO). However, studies to correlate imaging and PFTs have not been done.</p><p>There is no specific therapy for pulmonary fibrosis in SCD, other than attention to measures to prevent future episodes of ACS. (See  <a class="medical medical_review" href="/d/html/16353.html" rel="external">"Acute chest syndrome (ACS) in sickle cell disease (adults and children)", section on 'Prevention'</a>.)</p><p class="headingAnchor" id="H55815473"><span class="h1">SLEEP-DISORDERED BREATHING</span><span class="headingEndMark"> — </span>Sleep-disordered breathing (SDB), which is commonly due to obstructive sleep apnea (OSA), has been identified as an important comorbidity in SCD that may contribute to the frequency of acute pain episodes and possibly chronic cardiopulmonary disease [<a href="#rid56">56</a>]. Nocturnal desaturations can occur with or without the coexistence of OSA; their etiology is not well defined. SDB is underappreciated and, consequently, often undertreated in SCD. A standardized approach for screening and treating these patients has not been developed.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence</strong> – Many patients with SCD and SDB do not report symptoms of SDB, yet the prevalence of SDB appears to be higher than in the general population. In the Sleep and Asthma Cohort Study, 243 children unselected for symptoms of OSA underwent full-channel, in-laboratory polysomnography [<a href="#rid57">57</a>]. Using various obstructive apnea hypopnea indices (OAHI), OSA was present in 100 (41 percent) or 25 (10 percent) children at cutpoints of ≥1 or ≥5, respectively.</p><p></p><p class="bulletIndent1">One prospective study of 32 consecutive adults with Hb SS found SDB in 44 percent with a mean apnea-hypopnea index (AHI) of 17/hour (95% CI 10-24/hour) [<a href="#rid58">58</a>]. Another small prospective study of 20 adults between 21 and 30 years of age found that 10 had an AHI &gt;5 consistent with OSA irrespective of symptoms; this was associated with reduced health-related quality of life and increased systolic blood pressures. Interestingly, OSA in these patients was not associated with either obesity or a history of snoring [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology</strong> – The etiology of SDB is not well understood in SCD. Children and adolescents with SCD have reduced upper airway diameters and increased adenoid and tonsillar size (known risk factors for OSA) compared with volunteers without SCD [<a href="#rid60">60</a>]. It has been presumed that OSA is the primary cause of nocturnal hypoxemia in SCD, but this is not necessarily the case. In one study of 20 patients with nocturnal hypoxemia, 12 did not have obstructive events during a 16-channel polysomnogram (PSG) [<a href="#rid61">61</a>], which may explain why adenotonsillectomy fails to correct hypoxemia in some patients [<a href="#rid62">62</a>]. In the Sleep and Asthma cohort, among 243 children with sickle cell anemia, the only independent risk factors for moderate to severe OSA were habitual snoring and pulse oxygen saturation (SpO<sub>2</sub>) &lt;96 percent while awake [<a href="#rid57">57</a>]. A model incorporating these two risk factors had a negative predictive value of 0.99 but a positive predictive value of only 0.32 for OSA documented by polysomnography. (See  <a class="medical medical_review" href="/d/html/97855.html" rel="external">"Adenotonsillectomy for obstructive sleep apnea in children", section on 'High-risk populations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nocturnal hypoxemia and hypoventilation</strong> – Gas exchange abnormalities in SCD are not limited to hypoxemia. In a study of 19 children with SCD and a history concerning for SDB, 12 met criteria for OSA [<a href="#rid63">63</a>]. When these patients were compared with 10 age-, sex-, and racially matched children with OSA without coexistent SCD, the children with SCD had a longer duration of oxygen desaturation, a lower oxygen saturation nadir, and a higher percentage of sleep time with end-tidal carbon dioxide levels &gt;50 mmHg, suggesting greater impairments of both oxygenation and ventilation. Furthermore, oxygen desaturations with sleep are associated with daytime hypoxemia in SCD, suggesting that the pathologic impact on the endothelium is not limited to sleep-related events [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1">A retrospective study in adults and children with SCD referred for a sleep study identified isolated nocturnal hypoxemia in both age groups, which was associated with reduced daytime oxygen saturations at rest, and markers of worsening anemia [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1">There is some evidence linking nocturnal hypoxemia with an increased rate of vaso-occlusive episodes [<a href="#rid66">66</a>], acute chest syndrome (ACS) [<a href="#rid67">67</a>], and cerebrovascular events [<a href="#rid68">68,69</a>], but these data are inconsistent [<a href="#rid70">70</a>]. Data from the Sleep and Asthma Cohort study did not find an association between low nocturnal SpO<sub>2</sub> or higher OAHI and vaso-occlusive pain or ACS episodes. Alternatively, higher mean nocturnal SpO<sub>2</sub> was associated with higher rates of severe acute pain episodes (incidence rate ratio 1.10, 95% CI 1.03-1.18) [<a href="#rid71">71</a>]. However, adult studies have shown an association between OSA, nocturnal hypoxemia, and priapism among men with SCD [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent1">Treatment with <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> may reduce nocturnal hypoxemia. In a retrospective study, 37 children with SCD receiving hydroxyurea were compared with 104 who were not [<a href="#rid73">73</a>]. The hydroxyurea group had significantly higher nocturnal nadir in the median SpO<sub>2</sub> than the non-hydroxyurea group (91.4 and 85 percent saturation, respectively, p = 0.0002). The median sleep and awake SpO<sub>2</sub> values were also greater in the hydroxyurea group. No difference was observed in the AHI or the frequency of OSA. While promising, the observational nature of the study limits the conclusions that can be drawn in terms of the effect of hydroxyurea on clinical outcomes such as vaso-occlusive crises and sleep quality. (See  <a class="medical medical_review" href="/d/html/7071.html" rel="external">"Hydroxyurea use in sickle cell disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for polysomnography</strong> – Evaluation for OSA by polysomnography is usually performed in patients with complaints such as snoring, nonrestorative sleep, nocturnal gasping, choking, observed apneas during sleep, or daytime hypersomnolence, although it is possible that screening should be considered more broadly for children and adolescents with snoring, unexplained hypoxemia, recurrent acute chest or vaso-occlusive episodes, or enuresis. Because of the known association of OSA with pulmonary hypertension (PH) in non-SCD populations, the clinical guidelines for diagnosis of PH in SCD recommend a formal sleep study for all SCD patients with PH or an elevated tricuspid regurgitation velocity (TRV) on echocardiography [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/d/html/7706.html" rel="external">"Clinical presentation and diagnosis of obstructive sleep apnea in adults"</a> and  <a class="medical medical_review" href="/d/html/6363.html" rel="external">"Evaluation of suspected obstructive sleep apnea in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – The treatment of OSA complicating SCD is essentially the same as that in children and adults with OSA in the absence of SCD. In a small case series, treatment of SCD children with OSA produced a reduction in TRV [<a href="#rid74">74</a>].</p><p></p><p class="bulletIndent1">While SDB may be exacerbated by adenoid and tonsillar hypertrophy, adenotonsillectomy is often not curative in patients with SCD, and the impact on cardiopulmonary outcomes is unclear. Nonetheless, children and adolescents with SCD and OSA should be evaluated for adenotonsillar hypertrophy, as adenotonsillectomy can be curative in some patients. (See  <a class="medical medical_review" href="/d/html/6373.html" rel="external">"Management of obstructive sleep apnea in children"</a> and  <a class="medical medical_review" href="/d/html/7695.html" rel="external">"Obstructive sleep apnea: Overview of management in adults"</a>.)</p><p></p><p class="headingAnchor" id="H4234942531"><span class="h1">TRANSFUSION-RELATED ACUTE LUNG INJURY</span><span class="headingEndMark"> — </span>Since patients with SCD receive blood transfusions, they may develop transfusion-related acute lung injury (TRALI) [<a href="#rid75">75</a>]. A low threshold to suspect TRALI is important in this population. Details regarding diagnosis and management of TRALI are provided separately. (See  <a class="medical medical_review" href="/d/html/7926.html" rel="external">"Transfusion-related acute lung injury (TRALI)"</a> and  <a class="medical medical_review" href="/d/html/95132.html" rel="external">"Approach to the patient with a suspected acute transfusion reaction"</a>.)</p><p class="headingAnchor" id="H27"><span class="h1">SICKLE CELL TRAIT</span><span class="headingEndMark"> — </span>Respiratory dysfunction is rare in patients with sickle cell trait (SCT). Minimal, if any, differences in exercise tolerance and pulmonary function have been observed either at sea level or at higher altitudes when comparing individuals with SCT and matched controls who have normal hemoglobin. One area of growing concern is the risk of venous thromboembolism (VTE) in patients with SCT. Several studies have demonstrated that SCT is a modest VTE risk factor, with an overall 1.5- to 2-fold increased risk of VTE comparing SCT carriers with noncarriers [<a href="#rid76">76</a>]. More specifically, a meta-analysis has shown that compared with controls, SCT is associated with a higher risk for pulmonary embolism (PE) (pooled odds ratio [OR] 2.1, 95% CI 1.2-3.8) but not of deep vein thrombosis (DVT) (pooled OR 1.2, 95% CI 0.9-1.7) [<a href="#rid49">49</a>]. Pulmonary infarction, acute chest syndrome, and sudden death during intense military training have rarely been reported and are discussed separately. (See  <a class="medical medical_review" href="/d/html/7145.html" rel="external">"Sickle cell trait", section on 'Rhabdomyolysis and sudden death during strenuous physical activity'</a>.)</p><p class="headingAnchor" id="H628833876"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110843.html" rel="external">"Society guideline links: Sickle cell disease and thalassemias"</a>.)</p><p class="headingAnchor" id="H1301116857"><span class="h1">PATIENT PERSPECTIVE TOPIC</span><span class="headingEndMark"> — </span>Patient perspectives are provided for selected disorders to help clinicians better understand the patient experience and patient concerns. These narratives may offer insights into patient values and preferences not included in other UpToDate topics. (See  <a class="medical medical_review" href="/d/html/132604.html" rel="external">"Patient perspective: Sickle cell disease"</a>.)</p><p class="headingAnchor" id="H18977349"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact of pulmonary complications</strong> – Chronic pulmonary complications contribute substantially to morbidity and mortality in sickle cell disease (SCD). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute chest syndrome</strong> – Acute chest syndrome (ACS; defined as a new opacity of chest radiograph with fever and/or respiratory symptoms) is the most common form of acute pulmonary disease in SCD, occurring in almost one-half of patients. ACS is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/16353.html" rel="external">"Acute chest syndrome (ACS) in sickle cell disease (adults and children)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic dyspnea</strong> – Dyspnea is a common yet underreported symptom in SCD, particularly in adults. Questions that may help elicit a history of dyspnea and alert clinicians to the need for further evaluation are provided in the table  (<a class="graphic graphic_table graphicRef94508" href="/d/graphic/94508.html" rel="external">table 1</a>). (See <a class="local">'Chronic dyspnea'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PFT abnormalities</strong> – Pulmonary function tests (PFTs) are often abnormal in SCD. A restrictive pattern is the most common pattern among adults, while an obstructive pattern is more common in children. (See <a class="local">'Pulmonary function test abnormalities'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asthma</strong> – Asthma is an important disease modifier in SCD: Children with a history of ACS are more likely to develop asthma, and those with asthma are more susceptible to ACS. Intermittent or chronic respiratory symptoms and wheezing should lead to an evaluation for asthma. (See <a class="local">'Asthma'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary hypertension</strong> – Pulmonary hypertension (PH) is a relatively frequent and severe complication of SCD and an independent risk factor for mortality. PH may be suspected on the basis of exertional dyspnea and noninvasive testing, but definitive diagnosis requires right heart catheterization with demonstration of a resting mean pulmonary arterial pressure (mPAP) ≥25 mmHg  (<a class="graphic graphic_algorithm graphicRef94509" href="/d/graphic/94509.html" rel="external">algorithm 1</a>). (See <a class="local">'Pulmonary hypertension'</a> above and  <a class="medical medical_review" href="/d/html/94999.html" rel="external">"Pulmonary hypertension associated with sickle cell disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thromboembolism</strong> – The risks of venous thromboembolism (VTE) and pulmonary artery thrombosis are increased in SCD. Screening tests such as the D-dimer and clinical scoring systems are not reliable in SCD, so we typically perform a computed tomography pulmonary angiogram (CTPA) when acute VTE is suspected. Due to the risks of anticoagulation in patients with anemia due to SCD, we typically delay full anticoagulation pending the results of the CTPA unless the clinical suspicion is high. (See <a class="local">'Venous thromboembolism and pulmonary thrombosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary fibrosis</strong> – Pulmonary fibrosis (chronic scarring of the lung parenchyma) is another potential cause of dyspnea and is occasionally seen in patients with recurrent episodes of ACS with pulmonary infarction. There is no specific therapy other than attention to measures to prevent future episodes of ACS. (See <a class="local">'Pulmonary fibrosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sleep-disordered breathing</strong> – Sleep-disordered breathing (nocturnal hypoxemia and obstructive sleep apnea [OSA]) is common in children and adolescents with SCD. The prevalence in adults is not completely clear, but a high index of clinical suspicion is warranted. Tonsillectomy and adenoidectomy may be curative in some children with OSA. (See <a class="local">'Sleep-disordered breathing'</a> above.)</p><p></p><p class="headingAnchor" id="H3533515909"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>UpToDate gratefully acknowledges Stanley L Schrier, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Hematology.</p><p>The UpToDate editorial staff also acknowledges Harrison Farber, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Machado RF, Gladwin MT. Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension. Br J Haematol 2005; 129:449.</a></li><li><a class="nounderline abstract_t">Gladwin MT, Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med 2008; 359:2254.</a></li><li><a class="nounderline abstract_t">Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997; 337:762.</a></li><li><a class="nounderline abstract_t">Lopinto J, Elabbadi A, Gibelin A, et al. Infectious aetiologies of severe acute chest syndrome in sickle-cell adult patients, combining conventional microbiological tests and respiratory multiplex PCR. Sci Rep 2021; 11:4837.</a></li><li><a class="nounderline abstract_t">Klings ES, Anton Bland D, Rosenman D, et al. Pulmonary arterial hypertension and left-sided heart disease in sickle cell disease: clinical characteristics and association with soluble adhesion molecule expression. Am J Hematol 2008; 83:547.</a></li><li><a class="nounderline abstract_t">Klings ES, Machado RF, Barst RJ, et al. An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med 2014; 189:727.</a></li><li><a class="nounderline abstract_t">Boyd JH, Macklin EA, Strunk RC, DeBaun MR. Asthma is associated with acute chest syndrome and pain in children with sickle cell anemia. Blood 2006; 108:2923.</a></li><li><a class="nounderline abstract_t">DeBaun MR, Strunk RC. The intersection between asthma and acute chest syndrome in children with sickle-cell anaemia. Lancet 2016; 387:2545.</a></li><li><a class="nounderline abstract_t">Knight-Madden JM, Forrester TS, Lewis NA, Greenough A. Asthma in children with sickle cell disease and its association with acute chest syndrome. Thorax 2005; 60:206.</a></li><li><a class="nounderline abstract_t">Leong MA, Dampier C, Varlotta L, Allen JL. Airway hyperreactivity in children with sickle cell disease. J Pediatr 1997; 131:278.</a></li><li><a class="nounderline abstract_t">Koumbourlis AC, Zar HJ, Hurlet-Jensen A, Goldberg MR. Prevalence and reversibility of lower airway obstruction in children with sickle cell disease. J Pediatr 2001; 138:188.</a></li><li><a class="nounderline abstract_t">Willen SM, Rodeghier M, DeBaun MR. Asthma in children with sickle cell disease. Curr Opin Pediatr 2019; 31:349.</a></li><li><a class="nounderline abstract_t">Glassberg JA, Strunk R, DeBaun MR. Wheezing in children with sickle cell disease. Curr Opin Pediatr 2014; 26:9.</a></li><li><a class="nounderline abstract_t">Field JJ, DeBaun MR. Asthma and sickle cell disease: two distinct diseases or part of the same process? Hematology Am Soc Hematol Educ Program 2009; :45.</a></li><li><a class="nounderline abstract_t">Ozbek OY, Malbora B, Sen N, et al. Airway hyperreactivity detected by methacholine challenge in children with sickle cell disease. Pediatr Pulmonol 2007; 42:1187.</a></li><li><a class="nounderline abstract_t">Sen N, Kozanoglu I, Karatasli M, et al. Pulmonary function and airway hyperresponsiveness in adults with sickle cell disease. Lung 2009; 187:195.</a></li><li><a class="nounderline abstract_t">Willen SM, Rodeghier M, Strunk RC, et al. Aeroallergen sensitization predicts acute chest syndrome in children with sickle cell anaemia. Br J Haematol 2018; 180:571.</a></li><li><a class="nounderline abstract_t">Minter KR, Gladwin MT. Pulmonary complications of sickle cell anemia. A need for increased recognition, treatment, and research. Am J Respir Crit Care Med 2001; 164:2016.</a></li><li><a class="nounderline abstract_t">Klings ES, Wyszynski DF, Nolan VG, Steinberg MH. Abnormal pulmonary function in adults with sickle cell anemia. Am J Respir Crit Care Med 2006; 173:1264.</a></li><li><a class="nounderline abstract_t">Knight-Madden JM, Forrester TS, Lewis NA, Greenough A. The impact of recurrent acute chest syndrome on the lung function of young adults with sickle cell disease. Lung 2010; 188:499.</a></li><li><a class="nounderline abstract_t">O Dosunmu A, A Akinola R, A Onakoya J, et al. Pattern of chronic lung lesions in adults with sickle cell disease in Lagos, Nigeria. Caspian J Intern Med 2013; 4:754.</a></li><li><a class="nounderline abstract_t">Anthi A, Machado RF, Jison ML, et al. Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med 2007; 175:1272.</a></li><li><a class="nounderline abstract_t">Field JJ, Glassberg J, Gilmore A, et al. Longitudinal analysis of pulmonary function in adults with sickle cell disease. Am J Hematol 2008; 83:574.</a></li><li><a class="nounderline abstract_t">Hodges B, Ivy Z, Cronin RM, et al. Annual decline in lung function in adults with sickle cell disease is similar to that observed in adults with cystic fibrosis. Blood Adv 2022; 6:1937.</a></li><li><a class="nounderline abstract_t">Kassim AA, Payne AB, Rodeghier M, et al. Low forced expiratory volume is associated with earlier death in sickle cell anemia. Blood 2015; 126:1544.</a></li><li><a class="nounderline abstract_t">Mehari A, Klings ES. Chronic Pulmonary Complications of Sickle Cell Disease. Chest 2016; 149:1313.</a></li><li><a class="nounderline abstract_t">Arteta M, Campbell A, Nouraie M, et al. Abnormal pulmonary function and associated risk factors in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol 2014; 36:185.</a></li><li><a class="nounderline abstract_t">Koumbourlis AC. Lung function in sickle cell disease. Paediatr Respir Rev 2014; 15:33.</a></li><li><a class="nounderline abstract_t">Intzes S, Kalpatthi RV, Short R, Imran H. Pulmonary function abnormalities and asthma are prevalent in children with sickle cell disease and are associated with acute chest syndrome. Pediatr Hematol Oncol 2013; 30:726.</a></li><li><a class="nounderline abstract_t">Cohen RT, Strunk RC, Rodeghier M, et al. Pattern of Lung Function Is Not Associated with Prior or Future Morbidity in Children with Sickle Cell Anemia. Ann Am Thorac Soc 2016; 13:1314.</a></li><li><a class="nounderline abstract_t">Friedman D, Dozor AJ, Milner J, et al. Stable to improved cardiac and pulmonary function in children with high-risk sickle cell disease following haploidentical stem cell transplantation. Bone Marrow Transplant 2021; 56:2221.</a></li><li><a class="nounderline abstract_t">Lunt A, McGhee E, Sylvester K, et al. Longitudinal assessment of lung function in children with sickle cell disease. Pediatr Pulmonol 2016; 51:717.</a></li><li><a class="nounderline abstract_t">Willen SM, Cohen R, Rodeghier M, et al. Age is a predictor of a small decrease in lung function in children with sickle cell anemia. Am J Hematol 2018; 93:408.</a></li><li><a class="nounderline abstract_t">Uong EC, Boyd JH, DeBaun MR. Daytime pulse oximeter measurements do not predict incidence of pain and acute chest syndrome episodes in sickle cell anemia. J Pediatr 2006; 149:707.</a></li><li><a class="nounderline abstract_t">Quinn CT, Ahmad N. Clinical correlates of steady-state oxyhaemoglobin desaturation in children who have sickle cell disease. Br J Haematol 2005; 131:129.</a></li><li><a class="nounderline abstract_t">Campbell A, Minniti CP, Nouraie M, et al. Prospective evaluation of haemoglobin oxygen saturation at rest and after exercise in paediatric sickle cell disease patients. Br J Haematol 2009; 147:352.</a></li><li><a class="nounderline abstract_t">Rackoff WR, Kunkel N, Silber JH, et al. Pulse oximetry and factors associated with hemoglobin oxygen desaturation in children with sickle cell disease. Blood 1993; 81:3422.</a></li><li><a class="nounderline abstract_t">Halphen I, Elie C, Brousse V, et al. Severe nocturnal and postexercise hypoxia in children and adolescents with sickle cell disease. PLoS One 2014; 9:e97462.</a></li><li><a class="nounderline abstract_t">Naik RP, Streiff MB, Lanzkron S. Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know. J Thromb Thrombolysis 2013; 35:352.</a></li><li><a class="nounderline abstract_t">Haupt HM, Moore GW, Bauer TW, Hutchins GM. The lung in sickle cell disease. Chest 1982; 81:332.</a></li><li><a class="nounderline abstract_t">Oppenheimer EH, Esterly JR. Pulmonary changes in sickle cell disease. Am Rev Respir Dis 1971; 103:858.</a></li><li><a class="nounderline abstract_t">Haque AK, Gokhale S, Rampy BA, et al. Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. Hum Pathol 2002; 33:1037.</a></li><li><a class="nounderline abstract_t">Graham JK, Mosunjac M, Hanzlick RL, Mosunjac M. Sickle cell lung disease and sudden death: a retrospective/prospective study of 21 autopsy cases and literature review. Am J Forensic Med Pathol 2007; 28:168.</a></li><li><a class="nounderline abstract_t">Carstens GR, Paulino BBA, Katayama EH, et al. Clinical relevance of pulmonary vasculature involvement in sickle cell disease. Br J Haematol 2019; 185:317.</a></li><li><a class="nounderline abstract_t">Mekontso Dessap A, Deux JF, Abidi N, et al. Pulmonary artery thrombosis during acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med 2011; 184:1022.</a></li><li><a class="nounderline abstract_t">Naik RP, Streiff MB, Haywood C Jr, et al. Venous thromboembolism in adults with sickle cell disease: a serious and under-recognized complication. Am J Med 2013; 126:443.</a></li><li><a class="nounderline abstract_t">Novelli EM, Huynh C, Gladwin MT, et al. Pulmonary embolism in sickle cell disease: a case-control study. J Thromb Haemost 2012; 10:760.</a></li><li><a class="nounderline abstract_t">Stein PD, Beemath A, Meyers FA, et al. Deep venous thrombosis and pulmonary embolism in hospitalized patients with sickle cell disease. Am J Med 2006; 119:897.e7.</a></li><li><a class="nounderline abstract_t">Noubiap JJ, Temgoua MN, Tankeu R, et al. Sickle cell disease, sickle trait and the risk for venous thromboembolism: a systematic review and meta-analysis. Thromb J 2018; 16:27.</a></li><li><a class="nounderline abstract_t">Brunson A, Lei A, Rosenberg AS, et al. Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality. Br J Haematol 2017; 178:319.</a></li><li><a class="nounderline abstract_t">Brunson A, Keegan T, Mahajan A, et al. High incidence of venous thromboembolism recurrence in patients with sickle cell disease. Am J Hematol 2019; 94:862.</a></li><li><a class="nounderline abstract_t">Kabrhel C, Mark Courtney D, Camargo CA Jr, et al. Factors associated with positive D-dimer results in patients evaluated for pulmonary embolism. Acad Emerg Med 2010; 17:589.</a></li><li><a class="nounderline abstract_t">Shet AS, Wun T. How I diagnose and treat venous thromboembolism in sickle cell disease. Blood 2018; 132:1761.</a></li><li><a class="nounderline abstract_t">Powars D, Weidman JA, Odom-Maryon T, et al. Sickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure. Medicine (Baltimore) 1988; 67:66.</a></li><li><a class="nounderline abstract_t">Vij R, Machado RF. Pulmonary complications of hemoglobinopathies. Chest 2010; 138:973.</a></li><li><a class="nounderline abstract_t">Liguoro I, Arigliani M, Tan HL, Gupta A. The burden of sleep disordered breathing in children with sickle cell disease. Pediatr Pulmonol 2021; 56:3607.</a></li><li><a class="nounderline abstract_t">Rosen CL, Debaun MR, Strunk RC, et al. Obstructive sleep apnea and sickle cell anemia. Pediatrics 2014; 134:273.</a></li><li><a class="nounderline abstract_t">Sharma S, Efird JT, Knupp C, et al. Sleep disorders in adult sickle cell patients. J Clin Sleep Med 2015; 11:219.</a></li><li><a class="nounderline abstract_t">Whitesell PL, Owoyemi O, Oneal P, et al. Sleep-disordered breathing and nocturnal hypoxemia in young adults with sickle cell disease. Sleep Med 2016; 22:47.</a></li><li><a class="nounderline abstract_t">Strauss T, Sin S, Marcus CL, et al. Upper airway lymphoid tissue size in children with sickle cell disease. Chest 2012; 142:94.</a></li><li><a class="nounderline abstract_t">Needleman JP, Franco ME, Varlotta L, et al. Mechanisms of nocturnal oxyhemoglobin desaturation in children and adolescents with sickle cell disease. Pediatr Pulmonol 1999; 28:418.</a></li><li><a class="nounderline abstract_t">Rogers VE, Lewin DS, Winnie GB, Geiger-Brown J. Polysomnographic characteristics of a referred sample of children with sickle cell disease. J Clin Sleep Med 2010; 6:374.</a></li><li><a class="nounderline abstract_t">Kaleyias J, Mostofi N, Grant M, et al. Severity of obstructive sleep apnea in children with sickle cell disease. J Pediatr Hematol Oncol 2008; 30:659.</a></li><li><a class="nounderline abstract_t">Spivey JF, Uong EC, Strunk R, et al. Low daytime pulse oximetry reading is associated with nocturnal desaturation and obstructive sleep apnea in children with sickle cell anemia. Pediatr Blood Cancer 2008; 50:359.</a></li><li><a class="nounderline abstract_t">Worsham CM, Martin ST, Nouraie SM, et al. Clinical and laboratory findings associated with sleep disordered breathing in sickle cell disease. Am J Hematol 2017; 92:E649.</a></li><li><a class="nounderline abstract_t">Hargrave DR, Wade A, Evans JP, et al. Nocturnal oxygen saturation and painful sickle cell crises in children. Blood 2003; 101:846.</a></li><li><a class="nounderline abstract_t">Nourani AR, Fazlur Rahman AKM, Pernell B, et al. Nocturnal hypoxemia measured by polysomnogram is associated with acute chest syndrome in pediatric sickle cell disease. J Clin Sleep Med 2021; 17:219.</a></li><li><a class="nounderline abstract_t">Kirkham FJ, Hewes DK, Prengler M, et al. Nocturnal hypoxaemia and central-nervous-system events in sickle-cell disease. Lancet 2001; 357:1656.</a></li><li><a class="nounderline abstract_t">Dlamini N, Saunders DE, Bynevelt M, et al. Nocturnal oxyhemoglobin desaturation and arteriopathy in a pediatric sickle cell disease cohort. Neurology 2017; 89:2406.</a></li><li><a class="nounderline abstract_t">Brooks LJ, Koziol SM, Chiarucci KM, Berman BW. Does sleep-disordered breathing contribute to the clinical severity of sickle cell anemia? J Pediatr Hematol Oncol 1996; 18:135.</a></li><li><a class="nounderline abstract_t">Willen SM, Rodeghier M, Rosen CL, DeBaun MR. Sleep disordered breathing does not predict acute severe pain episodes in children with sickle cell anemia. Am J Hematol 2018; 93:478.</a></li><li><a class="nounderline abstract_t">Roizenblatt M, Figueiredo MS, Cançado RD, et al. Priapism is associated with sleep hypoxemia in sickle cell disease. J Urol 2012; 188:1245.</a></li><li><a class="nounderline abstract_t">Narang I, Kadmon G, Lai D, et al. Higher nocturnal and awake oxygen saturations in children with sickle cell disease receiving hydroxyurea therapy. Ann Am Thorac Soc 2015; 12:1044.</a></li><li><a class="nounderline abstract_t">Ambrusko SJ, Gunawardena S, Sakara A, et al. Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell disease. Pediatr Blood Cancer 2006; 47:907.</a></li><li><a class="nounderline abstract_t">Arzoun H, Srinivasan M, Adam M, et al. A Systematic Review on the Management of Transfusion-Related Acute Lung Injury in Transfusion-Dependent Sickle Cell Disease. Cureus 2022; 14:e22101.</a></li><li><a class="nounderline abstract_t">Pecker LH, Naik RP. The current state of sickle cell trait: implications for reproductive and genetic counseling. Hematology Am Soc Hematol Educ Program 2018; 2018:474.</a></li></ol></div><div id="topicVersionRevision">Topic 7121 Version 51.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15877728" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19020327" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pulmonary complications of sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9287233" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pathogenesis and treatment of sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33649379" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Infectious aetiologies of severe acute chest syndrome in sickle-cell adult patients, combining conventional microbiological tests and respiratory multiplex PCR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18383329" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pulmonary arterial hypertension and left-sided heart disease in sickle cell disease: clinical characteristics and association with soluble adhesion molecule expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24628312" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16690969" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Asthma is associated with acute chest syndrome and pain in children with sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27353685" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The intersection between asthma and acute chest syndrome in children with sickle-cell anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15741436" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Asthma in children with sickle cell disease and its association with acute chest syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9290616" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Airway hyperreactivity in children with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11174615" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prevalence and reversibility of lower airway obstruction in children with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31090576" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Asthma in children with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24370489" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Wheezing in children with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20008181" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Asthma and sickle cell disease: two distinct diseases or part of the same process?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17960821" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Airway hyperreactivity detected by methacholine challenge in children with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19301068" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pulmonary function and airway hyperresponsiveness in adults with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29363738" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Aeroallergen sensitization predicts acute chest syndrome in children with sickle cell anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11739128" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pulmonary complications of sickle cell anemia. A need for increased recognition, treatment, and research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16556694" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Abnormal pulmonary function in adults with sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20644948" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The impact of recurrent acute chest syndrome on the lung function of young adults with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24294468" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pattern of chronic lung lesions in adults with sickle cell disease in Lagos, Nigeria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17379852" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18383325" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Longitudinal analysis of pulmonary function in adults with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35015811" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Annual decline in lung function in adults with sickle cell disease is similar to that observed in adults with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26261241" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Low forced expiratory volume is associated with earlier death in sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26836905" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Chronic Pulmonary Complications of Sickle Cell Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24309610" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Abnormal pulmonary function and associated risk factors in children and adolescents with sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24268618" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Lung function in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23301782" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pulmonary function abnormalities and asthma are prevalent in children with sickle cell disease and are associated with acute chest syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27300316" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pattern of Lung Function Is Not Associated with Prior or Future Morbidity in Children with Sickle Cell Anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33958740" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Stable to improved cardiac and pulmonary function in children with high-risk sickle cell disease following haploidentical stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26694220" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Longitudinal assessment of lung function in children with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29226507" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Age is a predictor of a small decrease in lung function in children with sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17095349" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Daytime pulse oximeter measurements do not predict incidence of pain and acute chest syndrome episodes in sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16173973" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Clinical correlates of steady-state oxyhaemoglobin desaturation in children who have sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19694721" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Prospective evaluation of haemoglobin oxygen saturation at rest and after exercise in paediatric sickle cell disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7685205" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pulse oximetry and factors associated with hemoglobin oxygen desaturation in children with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24878576" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Severe nocturnal and postexercise hypoxia in children and adolescents with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23435703" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7056109" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The lung in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5089881" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pulmonary changes in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12395378" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17525572" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Sickle cell lung disease and sudden death: a retrospective/prospective study of 21 autopsy cases and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30739309" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Clinical relevance of pulmonary vasculature involvement in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21836136" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Pulmonary artery thrombosis during acute chest syndrome in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23582935" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Venous thromboembolism in adults with sickle cell disease: a serious and under-recognized complication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22417249" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pulmonary embolism in sickle cell disease: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17000225" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Deep venous thrombosis and pulmonary embolism in hospitalized patients with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30305805" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Sickle cell disease, sickle trait and the risk for venous thromboembolism: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28369826" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31074115" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : High incidence of venous thromboembolism recurrence in patients with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20624138" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Factors associated with positive D-dimer results in patients evaluated for pulmonary embolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29764840" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : How I diagnose and treat venous thromboembolism in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3336282" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Sickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20923801" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Pulmonary complications of hemoglobinopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34432958" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The burden of sleep disordered breathing in children with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25022740" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Obstructive sleep apnea and sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25515282" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Sleep disorders in adult sickle cell patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27544835" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Sleep-disordered breathing and nocturnal hypoxemia in young adults with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22241762" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Upper airway lymphoid tissue size in children with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10587416" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Mechanisms of nocturnal oxyhemoglobin desaturation in children and adolescents with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20726287" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Polysomnographic characteristics of a referred sample of children with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18776757" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Severity of obstructive sleep apnea in children with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17072857" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Low daytime pulse oximetry reading is associated with nocturnal desaturation and obstructive sleep apnea in children with sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28833466" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Clinical and laboratory findings associated with sleep disordered breathing in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12393400" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Nocturnal oxygen saturation and painful sickle cell crises in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33006312" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Nocturnal hypoxemia measured by polysomnogram is associated with acute chest syndrome in pediatric sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11425370" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Nocturnal hypoxaemia and central-nervous-system events in sickle-cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29117957" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Nocturnal oxyhemoglobin desaturation and arteriopathy in a pediatric sickle cell disease cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8846124" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Does sleep-disordered breathing contribute to the clinical severity of sickle cell anemia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29266432" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Sleep disordered breathing does not predict acute severe pain episodes in children with sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22902014" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Priapism is associated with sleep hypoxemia in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25970812" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Higher nocturnal and awake oxygen saturations in children with sickle cell disease receiving hydroxyurea therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16496290" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35165647" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A Systematic Review on the Management of Transfusion-Related Acute Lung Injury in Transfusion-Dependent Sickle Cell Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30504348" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : The current state of sickle cell trait: implications for reproductive and genetic counseling.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
